Inclusion Criteria: - Adult patients, >/= 18 years of age - Histologically or cytologically confirmed Stage III B or Stage IV squamous non-small cell lung cancer (NSCLC) - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - No prior chemotherapy for squamous NSCLC - Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR status is unknown - Radiographic evidence of disease Exclusion Criteria: - Prior systemic treatment for Stage IIIB or IV squamous NSCLC - NSCLC with histology classified as adenocarcinoma, large cell, mixed adenosquamous, or NSCLC not otherwise specified (NOS) - Prior exposure to experimental treatment targeting either the HGF or Met pathway - Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator - Uncontrolled brain metastases and treatment by neurosurgical resection or brain biopsy within 4 weeks prior to Day 1 of Cycle 1 - History of another malignancy in the previous 3 years except for prior history of in situ cancer or basal or squamous cell skin cancer - Pregnant or lactating women - Uncontrolled diabetes - Impaired bone marrow, liver or renal function as defined by protocol - Significant history of cardiovascular disease - Positive for HIV infection